{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:32:31Z","timestamp":1793147551420,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:00Z","timestamp":1793145600000},"content-version":"vor","delay-in-days":116,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["J-2101"],"award-info":[{"award-number":["J-2101"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["J-2101"],"award-info":[{"award-number":["J-2101"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["J-2101"],"award-info":[{"award-number":["J-2101"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dopa decarboxylase (DDC) is a candidate biomarker in Parkinson\u2019s disease (PD), but its levels are influenced by dopamine replacement therapy (DRT), complicating interpretation. We used high-throughput proteomics to analyze serum and CSF samples from PD patients, individuals with idiopathic REM-sleep behaviour disorder, and controls to assess DRT effects. In serum, DDC increased and prolactin and AOC3 decreased with higher levodopa equivalent daily doses, showing drug class-specific associations. Longitudinally, serum DDC and prolactin levels changed with DRT, while AOC3 remained stable. In CSF, DDC was elevated regardless of treatment, while prolactin was reduced only in treated PD. These results indicate that serum changes in DDC, prolactin, and AOC3 primarily reflect treatment exposure rather than disease biology. Our findings highlight the need to account for medication effects in proteomic studies, identify AOC3 as a novel DRT-sensitive protein, and support the potential of treatment-responsive proteins as pharmacodynamic markers in PD.<\/jats:p>","DOI":"10.1038\/s41531-026-01435-3","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:45:30Z","timestamp":1783187130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dopamine replacement therapy modulates DDC, prolactin and AOC3 levels in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Ludo","family":"van Hillegondsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Zerenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Groenewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wade-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avigail","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele T.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"1435_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"1435_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 5, 525\u2013535 (2006).","journal-title":"Lancet Neurol."},{"key":"1435_CR3","doi-asserted-by":"crossref","unstructured":"Yang, W. et al. Current and projected future economic burden of Parkinson\u2019s disease in the U.S. NPJ Parkinsons Dis. 6, 15 (2020).","DOI":"10.1038\/s41531-020-0117-1"},{"key":"1435_CR4","doi-asserted-by":"publisher","unstructured":"Winchester, L. et al. Identification of a possible proteomic biomarker in Parkinson\u2019s disease: discovery and replication in blood, brain and cerebrospinal fluid. Brain Commun. 5, https:\/\/doi.org\/10.1093\/BRAINCOMMS\/FCAC343 (2022).","DOI":"10.1093\/BRAINCOMMS\/FCAC343"},{"key":"1435_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-48961-3","volume":"15","author":"J H\u00e4llqvist","year":"2024","unstructured":"H\u00e4llqvist, J. et al. Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset. Nat. Commun. 15, 1\u201318 (2024).","journal-title":"Nat. Commun."},{"key":"1435_CR6","doi-asserted-by":"crossref","unstructured":"You, J. et al. Prediction of Future Parkinson Disease Using Plasma Proteins Combined with Clinical-Demographic Measures. Neurology 103, e209531 (2024).","DOI":"10.1212\/WNL.0000000000209531"},{"key":"1435_CR7","doi-asserted-by":"crossref","unstructured":"Karayel, O. et al. Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson\u2019s disease. Cell Rep. Med. 3, 100661 (2022).","DOI":"10.1016\/j.xcrm.2022.100661"},{"key":"1435_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira, J. B. et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging 3, 1201 (2023).","journal-title":"Nat Aging"},{"key":"1435_CR9","doi-asserted-by":"publisher","unstructured":"Rutledge, J. et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol. 147, https:\/\/doi.org\/10.1007\/S00401-024-02706-0 (2024).","DOI":"10.1007\/S00401-024-02706-0"},{"key":"1435_CR10","doi-asserted-by":"publisher","unstructured":"Paslawski, W. et al. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease. Transl. Neurodegener. 12, https:\/\/doi.org\/10.1186\/S40035-023-00374-W (2023).","DOI":"10.1186\/S40035-023-00374-W"},{"key":"1435_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-024-00421-0","volume":"13","author":"E Appleton","year":"2024","unstructured":"Appleton, E. et al. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson\u2019s disease. Transl. Neurodegener. 13, 1\u20134 (2024).","journal-title":"Transl. Neurodegener."},{"key":"1435_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52768-7","volume":"16","author":"K Bolsewig","year":"2025","unstructured":"Bolsewig, K. et al. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nat. Commun. 16, 1 (2025).","journal-title":"Nat. Commun."},{"key":"1435_CR13","doi-asserted-by":"crossref","unstructured":"van Rumund, A. et al. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinsons Dis. 7, 100661 (2021).","DOI":"10.1038\/s41531-021-00172-z"},{"key":"1435_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M del Campo","year":"2023","unstructured":"del Campo, M. et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u00b4s disease. Nat. Commun. 14, 5635 (2023).","journal-title":"Nat. Commun."},{"key":"1435_CR15","doi-asserted-by":"crossref","unstructured":"Blaess S., Stott S. R. W. & Ang S. L. The generation of midbrain dopaminergic neurons. Patterning and Cell Type Specification in the Developing CNS and PNS: Comprehensive Developmental Neuroscience, Second Edition. Published online 369\u2013398 (2020).","DOI":"10.1016\/B978-0-12-814405-3.00017-5"},{"key":"1435_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1212\/WNL.36.3.393","volume":"36","author":"A Laihinen","year":"1986","unstructured":"Laihinen, A. & Rinne, U. K. Function of dopamine receptors in Parkinson\u2019s disease: prolactin responses. Neurology 36, 393\u2013395 (1986).","journal-title":"Neurology"},{"key":"1435_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/jcem-51-1-152","volume":"51","author":"DL Kleinberg","year":"1980","unstructured":"Kleinberg, D. L. et al. Pergolide Mesylate: A Potent Day-Long Inhibitor of Prolactin in Rhesus Monkeys and Patients with Parkinson\u2019s Disease. J. Clin. Endocrinol. Metab. 51, 152\u2013154 (1980).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1435_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/jcem-47-4-807","volume":"47","author":"RD Bell","year":"1978","unstructured":"Bell, R. D., Carruth, A., Rosenberg, R. N. & Boyar, R. M. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson\u2019s disease. J. Clin. Endocrinol. Metab. 47, 807\u2013811 (1978).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1435_CR19","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1210\/clinem\/dgad545","volume":"109","author":"LJ Heneghan","year":"2024","unstructured":"Heneghan, L. J. et al. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. J. Clin. Endocrinol. Metab. 109, e667\u2013e674 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1435_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ane.12334","volume":"131","author":"M Nitkowska","year":"2015","unstructured":"Nitkowska, M., Tomasiuk, R., Czyzyk, M. & Friedman, A. Prolactin and sex hormones levels in males with Parkinson\u2019s disease. Acta. Neurol. Scand. 131, 411\u2013416 (2015).","journal-title":"Acta. Neurol. Scand."},{"key":"1435_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000519552","volume":"29","author":"H Duc Nguyen","year":"2022","unstructured":"Duc Nguyen, H. et al. Association between Serum Prolactin Levels and Neurodegenerative Diseases: Systematic Review and Meta-Analysis. Neuroimmunomodulation 29, 85\u201396 (2022).","journal-title":"Neuroimmunomodulation"},{"key":"1435_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1210\/jcem-46-4-576","volume":"46","author":"J Assies","year":"1978","unstructured":"Assies, J., Schellekens, A. P. M. & Touber, J. L. Prolactin in human cerebrospinal fluid. J. Clin. Endocrinol. Metab. 46, 576 (1978).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1435_CR23","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/0306-4522(82)90103-8","volume":"7","author":"ND Martensz","year":"1982","unstructured":"Martensz, N. D. & Herbert, J. Relationship between prolactin in the serum and cerebrospinal fluid of ovariectomized female rhesus monkeys. Neuroscience 7, 2801\u20132812 (1982).","journal-title":"Neuroscience"},{"key":"1435_CR24","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/jnnp.43.11.1012","volume":"43","author":"NF Lawton","year":"1980","unstructured":"Lawton, N. F. & Macdermot, J. Abnormal regulation of prolactin release in idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 43, 1012\u20131015 (1980).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1435_CR25","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/WNL.31.10.1356","volume":"31","author":"T Eisler","year":"1981","unstructured":"Eisler, T., Thorner, M. O., Macleod, R. M., Kaiser, D. L. & Calne, D. B. Prolactin secretion in Parkinson disease. Neurology 31, 1356\u20131359 (1981).","journal-title":"Neurology"},{"key":"1435_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur, C. V. M. et al. Randomized Delayed-Start Trial of Levodopa in Parkinson\u2019s Disease. N. Engl. J. Med. 380, 315\u2013324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1435_CR27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00702-024-02825-8","volume":"131","author":"WH Jost","year":"2024","unstructured":"Jost, W. H. Dopamine agonists in the treatment of Parkinson\u2019s disease: the show must go on. J. Neural Transm. 131, 1471\u20131480 (2024).","journal-title":"J. Neural Transm."},{"key":"1435_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/ars.2017.7418","volume":"30","author":"M Salmi","year":"2019","unstructured":"Salmi, M. & Jalkanen, S. Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation. Antioxid. Redox Signal 30, 314\u2013332 (2019).","journal-title":"Antioxid. Redox Signal"},{"key":"1435_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42398-w","volume":"14","author":"PN Newsome","year":"2023","unstructured":"Newsome, P. N. et al. A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis. Nat. Commun. 14, 7151 (2023).","journal-title":"Nat. Commun."},{"key":"1435_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00288-7","volume":"7","author":"DS Boyer","year":"2021","unstructured":"Boyer, D. S. et al. Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy. Int. J. Retina Vitreous 7, 30 (2021).","journal-title":"Int. J. Retina Vitreous"},{"key":"1435_CR31","doi-asserted-by":"crossref","unstructured":"Li, H. Y. et al. Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes. PLoS One 11, e0147981 (2016).","DOI":"10.1371\/journal.pone.0147981"},{"key":"1435_CR32","doi-asserted-by":"crossref","unstructured":"Schilter, H. C., et al. Effects of an anti-inflammatory VAP-1\/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. Respir. Res. 16, 42 (2015).","DOI":"10.1186\/s12931-015-0200-z"},{"key":"1435_CR33","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/0024-3205(95)02153-A","volume":"57","author":"F Boomsma","year":"1995","unstructured":"Boomsma, F., van den Meiracker, A., Man in \u2019t Veld, A. & Schalekamp, M. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson\u2019s disease. Life Sci. 57, 1753\u20131759 (1995).","journal-title":"Life Sci."},{"key":"1435_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/0006-2952(82)90037-5","volume":"31","author":"GA Lyles","year":"1982","unstructured":"Lyles, G. A. & Callingham, B. A. In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues. Biochem. Pharm. 31, 1417\u20131424 (1982).","journal-title":"Biochem. Pharm."},{"key":"1435_CR35","unstructured":"Study Details | NCT05904717 | Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05904717 Accessed January 26, (2026)."},{"key":"1435_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"1435_CR37","unstructured":"International Classification of Sleep Disorders Third Edition. Published online 2014."},{"key":"1435_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ana.24385","volume":"77","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann. Neurol. 77, 830\u2013839 (2015).","journal-title":"Ann. Neurol."},{"key":"1435_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1435_CR40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1435_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade, S., Mollenhauer, B. & Trenkwalder, C. Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide. Mov. Disord. Clin. Pr. 7, 343\u2013345 (2020).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1435_CR42","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"1435_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/mds.25748","volume":"29","author":"MTM Hu","year":"2014","unstructured":"Hu, M. T. M. et al. Predictors of cognitive impairment in an early stage Parkinson\u2019s disease cohort. Mov. Disord. 29, 351\u2013359 (2014).","journal-title":"Mov. Disord."},{"key":"1435_CR44","doi-asserted-by":"crossref","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9, e95192 (2014).","DOI":"10.1371\/journal.pone.0095192"},{"key":"1435_CR45","unstructured":"Taylor, A. & Fletcher, M. P. easyplater: The easy way to generate microplate designs deconvolved from multivariate clinical data https:\/\/arxiv.org\/abs\/2512.17988v2 (2026). Published online December 19, 2025. Accessed."},{"key":"1435_CR46","unstructured":"Olink\u00ae Explore 3072 User Manual."},{"key":"1435_CR47","unstructured":"Olink\u00ae Explore HT Overview User Manual."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01435-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:38:56Z","timestamp":1793144336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01435-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01435-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7232697\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"263"}}